Targetable molecular pathways in classical Hodgkin's lymphoma. - Wikidata - wikimedia - TriplyDB

Targetable molecular pathways in classical Hodgkin's lymphoma.

Targetable molecular pathways in classical Hodgkin's lymphoma.

http://www.wikidata.org/entity/Q37825891

about

Children's Oncology Group's 2013 blueprint for research: Hodgkin lymphoma.EGCG targeting efficacy of NF-κB downstream gene products is dictated by the monocytic/macrophagic differentiation status of promyelocytic leukemia cells.

P2860

Q38068839-0B264440-80A5-4E57-A91F-8418EACEC329 Q39329646-19051956-80D6-4EEE-985A-5EF9C6F0630C

P2860

Targetable molecular pathways in classical Hodgkin's lymphoma.

http://www.wikidata.org/entity/Q37825891

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 04 January 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Targetable molecular pathways in classical Hodgkin's lymphoma.

@en

Targetable molecular pathways in classical Hodgkin's lymphoma.

@nl

type

label

Targetable molecular pathways in classical Hodgkin's lymphoma.

@en

Targetable molecular pathways in classical Hodgkin's lymphoma.

@nl

prefLabel

Targetable molecular pathways in classical Hodgkin's lymphoma.

@en

Targetable molecular pathways in classical Hodgkin's lymphoma.

@nl

P1433

Q37825891-47528324-8B01-47EA-8F39-D50D5CFB6C54

P1476

Q37825891-0FD7481B-565D-4864-91F7-030DE6035B60

P2093

Q37825891-347A427E-42D4-40EA-A5C2-B9CCB2ED8C40

Q37825891-67B772DA-5E98-42CD-81B4-B55C90389182

Q37825891-754503AF-EE09-40DA-8484-E0FE1841460F

P2860

Q37825891-021F19AE-7E8B-4999-8E53-36FF199399E2

Q37825891-04465D14-E8DF-43AE-880A-36A8F2094CA5

Q37825891-0608F425-0820-41A7-8441-4399A11EB3CC

Q37825891-062754F7-5BCF-479A-8EF2-EC3CC4BF2E79

Q37825891-0C48DD31-5078-4D56-B79C-9DD230F66998

Q37825891-0DD1E10D-B700-45FC-A76A-B5311BBBB20D

Q37825891-0F8A0189-0A71-46AD-8F9B-C1018AC740D5

Q37825891-1173BC7B-C60A-40EE-A329-950165178DB7

Q37825891-13B76A1C-D2CE-4405-BAE2-F80F2274558F

Q37825891-19A5850C-9FE2-4445-BA26-C7358F187F66

P304

Q37825891-CA490E5A-D21C-4F62-BF28-306168212FD9

P31

Q37825891-4d871402-51af-4849-b967-f2ded80ad4f5

Q37825891-898C3F8F-F090-4ECA-9657-319AF4FE6E79

P356

Q37825891-FBF02169-EA10-4AE2-B843-112E578747A7

P407

Q37825891-8527DD51-8997-447A-9F35-B28326DEA8DB

P433

Q37825891-1723353B-5729-4174-8601-04CFF56F9538

P478

Q37825891-63C22B3F-03DC-4F8F-B971-55E2E14817EE

P50

Q37825891-1DAFB51D-27CC-4884-BB8F-FEB44AF00D75

P577

Q37825891-1923CFDC-46C3-4CE3-AD45-75DC921CB676

P698

Q37825891-A3FAE9EE-D3DB-4FDA-86E6-C5CFCF7FED89

P356

13543784.2011.546562

P1433

Expert Opinion on Investigational Drugs

P1476

Targetable molecular pathways in classical Hodgkin's lymphoma

@en

P2093

Ellen C Obermann

http://www.w3.org/2001/XMLSchema#string

Heiner Adams

http://www.w3.org/2001/XMLSchema#string

Stephan Dirnhofer

http://www.w3.org/2001/XMLSchema#string

P2860

Hodgkin's disease and the Epstein-Barr virus.

Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD

ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi

Aberrant expression of the Th2 cytokine IL-21 in Hodgkin lymphoma cells regulates STAT3 signaling and attracts Treg cells via regulation of MIP-3alpha

Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia patients: a population-based study in Sweden

Percentage of activated cytotoxic T-lymphocytes in anaplastic large cell lymphoma and Hodgkin's disease: an independent biological prognostic marker.

Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation.

Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's

Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies.

Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206.

P304

141-151

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/13543784.2011.546562

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P50

Alexandar Tzankov

P577

2011-01-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21204722

http://www.w3.org/2001/XMLSchema#string